About SentoClone AB

SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defence system is activated and strengthened to combat cancer.

SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises)

SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D.

SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn.

Last Updated Tuesday, 29 June 2010 08:10

Attention: open in a new window. PDFPrint